Related Experiment Video
Updated: Jun 4, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
NCOA6 differentially regulates the expression of the CYP2C9 and CYP3A4 genes
Sailesh Surapureddi1, Ritu Rana, Joyce A Goldstein
1Laboratory of Toxicology and Pharmacology, National Institute of Environmental Health Sciences, P.O. Box 12233, Research Triangle Park, NC 27709, United States.
Abstract:
CYP2Cs and CYP3A4 sub families of enzymes of the Cytochrome P450 super family metabolize clinically prescribed therapeutics. Constitutive and induced expressions of these enzymes are under the control of HNF4α and rifampicin activated PXR. In the present study, we show a mechanism for ligand dependent synergistic cross talk between PXR and HNF4α. Two-hybrid screening identified NCOA6 as a HNF4α interacting protein. NCOA6 was also found to interact with PXR through the first LXXLL motif in GST pull down and mammalian two hybrid assays. NCOA6 enhances the synergistic activation of CYP2C9 and CYP3A4 promoter activity by PXR and HNF4α in the presence of rifampicin. However silencing NCOA6 abrogated the synergistic activation and induction of CYP2C9 by PXR-HNF4α but not of CYP3A4. ChIP analysis revealed that NCOA6 could bridge HNF4α and PXR binding sites of the CYP2C9 promoter. Our results indicate that NCOA6 is responsible for the synergistic activation of CYP2C9 by HNF4α and PXR and NCOA6 differentially regulates CYP2C9 and CYP3A4 gene expression though both the genes are regulated by the same nuclear receptors.
Insights
Nuclear receptors pregnane X receptor (PXR) and hepatocyte nuclear factor 4 alpha (HNF4α) synergistically regulate drug-metabolizing enzymes. NCOA6 acts as a bridge, mediating this interaction for CYP2C9 but not CYP3A4.
Area of Science:
- Pharmacology
- Molecular Biology
- Biochemistry
Background:
- Cytochrome P450 enzymes, specifically CYP2C and CYP3A subfamilies, are crucial for metabolizing prescribed medications.
- The expression of these enzymes is regulated by nuclear receptors, including hepatocyte nuclear factor 4 alpha (HNF4α) and rifampicin-activated pregnane X receptor (PXR).
Purpose of the Study:
- To elucidate the mechanism of ligand-dependent synergistic cross-talk between PXR and HNF4α.
- To investigate the role of NCOA6 in mediating the interaction between PXR and HNF4α in regulating CYP gene expression.
Main Methods:
- Two-hybrid screening to identify interacting proteins.
- GST pull-down and mammalian two-hybrid assays to confirm protein interactions.
- Reporter assays to assess promoter activity.
- NCOA6 silencing to evaluate its functional role.
- Chromatin immunoprecipitation (ChIP) analysis to determine promoter binding.
Main Results:
- NCOA6 was identified as an interacting protein for HNF4α and also interacts with PXR.
- NCOA6 enhances the synergistic activation of CYP2C9 and CYP3A4 promoter activity by PXR and HNF4α.
- Silencing NCOA6 abrogated the synergistic activation and induction of CYP2C9, but not CYP3A4, by PXR-HNF4α.
- ChIP analysis showed NCOA6 bridges PXR and HNF4α binding sites on the CYP2C9 promoter.
Conclusions:
- NCOA6 is essential for the synergistic activation of CYP2C9 gene expression by HNF4α and PXR.
- NCOA6 differentially regulates CYP2C9 and CYP3A4 gene expression, despite both being regulated by the same nuclear receptors.
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cell Specific Gene Expression
Regulation of Nuclear Protein Sorting
Regulation of Expression at Multiple Steps
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...

